Ipriflavone modulates IGF-I but is unable to restore bone in rats

Phytotherapy Research

Volumn 19, Issue 2, 2005, Pages 116-120

  Deyhim, Farzad ^a   Smith, Brenda J ^b   Soung, Do Y ^b   Juma, Shanil ^c   Devareddy, Latha ^b   Arjmandi, Bahrain H ^b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

IGF I; Ipriflavone; Osteoporosis; Rats

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ESTRADIOL; HYDROXYPROLINE; IPRIFLAVONE; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE MASS; CONTROLLED STUDY; FEMALE; FEMUR; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OVARIECTOMY; PROTEIN EXPRESSION; RAT; URINARY EXCRETION;

ANIMALS; BLOTTING, NORTHERN; BONE REMODELING; FEMALE; FEMUR; INSULIN-LIKE GROWTH FACTOR I; ISOFLAVONES; OSTEOPOROSIS; OVARIECTOMY; PHYTOTHERAPY; PLANTS, MEDICINAL; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 18444409917     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1615     Document Type: Article

References (27)

1. Adami S, Bufalino L, Cervetti R, et al. 1997. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporos Int 7: 119-125.
2. Agnusdei D, Adami S, Cervetti R, et al. 1992. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis. Bone Miner 19: S43-S48.
3. Agnusdei D, Crepaldi G, Isaia G, et al. 1997. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int 61: 142-147.
4. Alexandersen P, Toussaint A, Christiansen C, et al. 2001. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 285: 1482-1488.
5. Arjmandi BH, Alekel L, Mollis BW, et al. 1996. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J Nutr 126: 161-167.
6. Arjmandi BH, Birnbaum RS, Juma S, Barengolts E, Kukreja SC. 2000. The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms. Calcif Tissue Int 66: 61-65.
7. Arjmandi BH, Getlinger MJ, Goyal NV, et al. 1998. Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats. Am J Clin Nutr 68: 1358S-1363S.
8. Body JJ. 2002. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 30: 75S-79S.
9. Bruck B, Seitz D, Hanke S, et al. 1996. Bone mineral density in premenopausal women with oestrogen deficiency and symptomatic coronary heart disease. Br J Clin Pract 50: 450-453.
10. Chew V. 1997. Comparisons among Treatment Means in an Analysis of Variance. US Department of Agriculture. Hyttsville, MD, USA.
11. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.
12. Cosman F, Nieves J, Walliser J, Lindsay R. 1995. Post-menopausal osteoporosis: patient choices and outcomes. Maturitas 22: 137-143.
13. Daniel WE. 1991. Biostatistics: A Foundation for Analysis in the Health Sciences. John Wiley & Sons: New York, NY, USA.
14. Davidson MR. 2003. Pharmacotherapeutics for osteoporosis prevention and treatment. J Midwifery Womens Health 48: 39-52.
15. Kalu DN, Arjmandi BH, Liu CC, Salih MA, Birnbaum RS. 1994. Effects of ovariectomy and estrogen on the serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3. Bone Miner 25: 135-148.
16. Kuiper GG, Lemmen JG, Carlsson B, et al. 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 39: 4252-4263.
17. Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA. 2003. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J Bone Miner Res 18: 393-405.
18. Looker AC, Orwoll ES, Johnston CC Jr, et al. 1997. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12: 1761-1768.
19. Moreira Kulak CA, Schussheim DH, McMahon DJ, et al. 2000. Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr Pract 6: 296-304.
20. Nakamura S, Morimoto S, Takamoto S, et al. 1992. Effect of ipriflavone on bone mineral density and calcium-related factors in elderly females. Calcif Tissue Int 51: S30-S34.
21. Neer RM, Arnaud CD, Zanchetta JR, et al. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441.
22. Petilli M, Fiorelli G, Benvenuti S, Frediani U, Gori F, Brandi ML. 1995. Interactions between ipriflavone and the estrogen receptor. Calcif Tissue Int 56: 160-165.
23. Reginster J, Minne HW, Sorensen OH, et al. 2000. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11: 83-91.
24. Rosen CJ. 2001. Treatment of postmenopausal osteoporosis: an evidence-based approach. Rev Endocr Metab Disord 2: 35-43.
25. Srivastava M, Deal C. 2002. Osteoporosis in elderly: prevention and treatment. Clin Geriatr Med 18: 529-555.
26. Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K. 1997. Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 12: 1272-1279.
27. Zhang M, Xuan S, Bouxsein ML, et al. 2002. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J. Biol. Chem 277: 44005-44012.